Sugi Predict

Sugi Predict / Compounds / SCHEMBL2224982

SCHEMBL2224982

SCHEMBL2224982

N#Cc1ccccc1N1CCN(C(=O)c2cccc(-c3noc(C(F)(F)F)n3)c2)CC1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HDAC4 P56524 9/20 0.57
▸ HDAC6 Q9UBN7 3/20 0.51
▸ HDAC8 Q9BY41 2/20 0.51
▸ HDAC2 Q92769 1/20 0.51
▸ MGLL Q99685 2/20 0.49
▸ ALDH1A1 P00352 4/20 0.45
▸ NPSR1 Q6W5P4 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ TACR3 P29371 1/20 0.43
▸ NAMPT P43490 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ SLC6A7 Q99884 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2223637 0.88 ALDH1A1 (0.61) HDAC4HDAC6HDAC8HDAC2MGLL
SCHEMBL2228116 0.88 HDAC4 (0.60) HDAC4HDAC6HDAC8HDAC2MGLL
SCHEMBL2226069 0.88 KDM4E (0.55) HDAC4HDAC6HDAC8HDAC2ALDH1A1
SCHEMBL2229001 0.86 HDAC4 (0.52) HDAC4HDAC6HDAC8HDAC2MGLL
SCHEMBL2227789 0.85 HDAC4 (0.62) HDAC4HDAC6HDAC8HDAC2MGLL
SCHEMBL2224348 0.84 HDAC4 (0.56) HDAC4HDAC6HDAC8HDAC2ALDH1A1
SCHEMBL2223596 0.83 HDAC4 (0.52) HDAC4HDAC6HDAC8HDAC2MGLL
SCHEMBL2226665 0.82 HDAC4 (0.52) HDAC4HDAC6HDAC8HDAC2MGLL
SCHEMBL2227129 0.82 HDAC4 (0.71) HDAC4HDAC6HDAC8HDAC2MGLL
SCHEMBL2226604 0.82 SLC6A7 (0.62) HDAC4HDAC6HDAC8HDAC2MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013009827-A1 METHODS OF TREATMENT TEMPERO PHARMACEUTICALS, INC. (US) 2013-01-17 — — WO claimed
US-20120289495-A1 COMPOUNDS AND METHODS Tempero Pharmaceuticals Inc. 2012-11-15 — — US claimed
US-8981084-B2 Oxadiazole HDAC inhibitors TEMPERO PHARMACEUTICALS, INC. (US) 2015-03-17 — — US disclosed
US-8981084-B2 Oxadiazole HDAC inhibitors TEMPERO PHARMACEUTICALS, INC. (US) 2015-03-17 — — US disclosed
US-8981084-B2 Oxadiazole HDAC inhibitors TEMPERO PHARMACEUTICALS, INC. (US) 2015-03-17 — — US disclosed
WO-2013009827-A1 METHODS OF TREATMENT TEMPERO PHARMACEUTICALS, INC. (US) 2013-01-17 — — WO disclosed
EP-2523664-A1 COMPOUNDS AND METHODS Tempero Pharmaceuticals, Inc. (US) 2012-11-21 — — EP disclosed
US-20120289495-A1 COMPOUNDS AND METHODS Tempero Pharmaceuticals Inc. 2012-11-15 — — US disclosed
US-20120289495-A1 COMPOUNDS AND METHODS Tempero Pharmaceuticals Inc. 2012-11-15 — — US disclosed
US-20120289495-A1 COMPOUNDS AND METHODS Tempero Pharmaceuticals Inc. 2012-11-15 — — US disclosed
WO-2011088192-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2011-07-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289495-A1 COMPOUNDS AND METHODS XDH, CCNY, TOP2B HDAC4 2773/4885HDAC6 1763/4885HDAC8 2959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.